Progress in immunotherapy and molecular therapy for liver failure
-
摘要:
肝衰竭是一个多因素参与的复杂过程,针对各种肝衰竭相关细胞因子、受体的分子治疗成为近年的研究热点。肝衰竭的免疫治疗包括促进肝细胞再生、胸腺肽免疫调节等,免疫调节治疗结合传统治疗在临床得到广泛应用。通过对肝衰竭动物模型研究表明,导入ARC蛋白、肝细胞核因子4,可以保护肝细胞,促进肝细胞功能的恢复。靶向肝衰竭发病相关分子(纤维介素蛋白、凋亡相关分子、转化生长因子β、骨桥蛋白、核因子-κB、Toll样受体等)的阻断治疗,成功治愈了肝衰竭动物模型。目前分子治疗研究尚处于实验室阶段,为肝衰竭治疗提供了新的思路,但是缺乏临床研究数据。
Abstract:Liver failure is a complex process involving many factors. The molecular therapy targeting the cytokines and receptors associated with liver failure has become the research hotspots in recent years. Immunotherapy for liver failure includes promoting the regeneration of hepatocytes and immunoregulation by thymosin,and the combination of immunomodulatory therapy with traditional therapy is widely applied in clinical treatment. Research on the animal model of liver failure suggested that importing ARC protein or hepatocyte nuclear factor 4 protected hepatocytes and promoted the recovery of their function. Block therapy against liver failure-related molecules( fibrinogen-like protein 2,apoptosis-related molecules,transforming growth factor β,osteopontin,nuclear factor-κB,and Toll-like receptors,etc.) successfully cured the animal model of liver failure. The research on molecular therapy offers a new way for treatment of liver failure,but it is still in the stage of laboratory research at present and lacks clinical data.
-
Key words:
- liver failure /
- molecular therapy /
- immunotherapy /
- editorial
计量
- 文章访问数: 2311
- HTML全文浏览量: 16
- PDF下载量: 504
- 被引次数: 0